OBJECTIVE： To investigate the effects and safety of fructose sodium diphosphate on cardiac function， myocardial injury markers， ischemia modified albumin （IMA） and copeptin in patients with acute myocardial infarction （AMI）. METHODS： In retrospective study， 102 AMI patients were collected from Nanyang Second People’s Hospital during Feb. 2014-Apr. 2015， and then divided into observation group and control group according to therapy plan， with 51 cases in each group. Both groups received routine therapy and symptomatic therapy as intravenous dripping of urokinase+ intravenous pump of heparin+oral administration of aspirin. Observation group was additionally given fructose sodium diphosphate 10 g intravenously， bid. Treatment courses of 2 groups lasted for 7-10 d. The changes of cardiac function indexes （LVDd， LVSd， LVEF）， myocardial injury markers （cTnⅠ， CK-MB）， IMA and copeptin were recorded in 2 groups before and after treatment. The cardiac function grading， the occurrence of ADR and adverse events were also recorded in 2 groups. RESULTS： Before treatment， there was no statistical significance in above indexes between 2 groups （P＞0.05）. 12， 24 h after treatment， LVDd and LVSd of 2 groups were shortened significantly， while LVEF and IMA levels were increased significantly， and CK-MB and copeptin levels were decreased significantly， compared to before treatment； the improvement of observation group was significantly better than control group， with statistical significance （P＜0.05）. cTnⅠ levels of 2 groups were increased gradually compared to before treatment [there was no statistical significance in observation group between 12 h after treatment and before treatment （P＞0.05）]； the increase of observation group was significantly smaller than that of control group， with statistical significance （P＜0.05）. 24 h after treatment， the proportion of cardiac function Killip gradeⅠ-Ⅱ was 96.1％ in observation group， which significantly higher than 78.4％ in control group， with statistical significance （P＜0.05）. No severe ADR was found in 2 groups， and there was no statistical significance in the incidence of ADR （P＞0.05）. In respect of adverse events， the number of adverse events as severe arrhythmia， recurrent myocardial infarction， postinfarction angina pectoris and total incidence of ADE in observation group was significantly less or under than control group， with statistical significance （P＜0.05）， besides there was no statistical significance in mortality between 2 groups （P＞0.05）. CONCLUSIONS： Routine symptomatic treatment combined with sodium fructose diphosphate in the treatment of AMI can effectively increase myocardial injury markers， copeptin and IMA levels， improve cardiac function and reduce the risk of adverse events so as to improve the quality of prognosis.